Search PubMed⌕ Search

Biomedical subjects

N Inaba

Publications and source records attributed to N Inaba.

116 records · Page 7Linked to original sources
PubMed1981

[A study on the possible transmission of hepatitis B virus from HBsAg carrier women to their husbands (author's transl)].

In order to assess the possible sexual transmission of hepatitis B virus (HBV), the occurrence of post-marital acute hepatitis and the prevalence of hepatitis B surface antigen (HBsAg) and antibody (HBsAb) were investigated among the husbands of HBsAg carrier women. The possible infectious routes and influencing factors in the HBV infection of the husbands by their HBsAg carrier wives were also discussed. This study demonstrates: 1. In the husbands examined, the exposure marker of HBV was found to be 32.8 per cent and the occurrence rate of post-marital hepatitis came up to 7.2 per cent. 2. The transmission of HBV from HBsAg carrier women to their husbands was supposed to take place shortly after marriage. E-Ag and e-Ab in ther sera of HBsAg carrier women could serve respectively as indicators of positive and negative HBV transmission. In the husbands with wives whose serum HBsAg-titers by R-PHA were higher than 39, a high exposure marker of HBV (87.5%) was observed. 3. The results of HBsAg detection rates and titers in various kinds of body fluids obtained from HBsAg carrier women suggested that cervical mucus and vaginal discharge might play an important role in the sexual HBV transmission.

Carrier State↗
PubMed1980

Ectopic synthesis of pregnancy specific beta 1-glycoprotein (SP1) and placental specific tissue proteins (PP5, PP10, PP11, PP12) in nontrophoblastic malignant tumours. Possible markers in oncology.

By using an enzyme-bridge immunoperoxidase (PAP) technique, localization of so-called pregnancy-specific beta 1-glycoprotein (SP1) and placental-specific tissue proteins (PP5, PP10, PP11, PP12) was investigated in 19 cases of breast cancer, 24 cases of testicular malignant tumours, 12 cases of gastric cancer and some cases of other malignant tumours. These five glycoproteins isolated from human term placentae and characterized by Bohn are localised mainly in the cytoplasm, or nucleus of syncytiotrophoblast and appear to be specific for the trophoblast. But to a certain percentage these proteins could also be detected in the cytoplasma of malignant cells: In breast cancer, SP1 was present in 52.6% of cases, PP5 in 63.2%, PP10 in 68.4%, PP11 in 55.6% and PP12 in 31.6%. In testicular malignant tumours the detection rates of these proteins varied from 20.8 to 75.0% and in gastric cancer from 41.7 to 66.7%. In total 50% of the tumours tested were SP1-positive, 58.3% PP5-positive, 55.6% PP10-positive, 38.0% PP11-positive and 31.9% PP12-positive. In addition, it was found that mononuclear histiocytes showed a strong cytoplasmic staining for PP10 and PP12 and that a few other non-cancerous cells (i.e. striated cells in gastric metaplasia, gastric polyps etc.) stained for PP5, PP10, PP11 and/or PP12. All control sections were negative in malignant cells as well as in other tissue cells. This study confirms the reports that some kinds of malignant tumours produce SP1 and indicates that the ectopic production of proteins normally produced by the trophoblast is a common finding in malignant tumours. It furthermore suggests that such proteins may be useful as markers in monitoring patients with malignant diseases. The possible mechanisms of ectopic production of these inappropriate proteins in malignant tumours are discussed.

Breast Neoplasms↗
PubMed1980

Immunohistochemical location of placental proteins (PP8, 9, 10, 11, 12) in human term placentae.

By using an immunoglobulin enzyme bridge (PAP) technique, the location of two ubiquitous tissue proteins (PP8, PP9) and three placental specific tissue proteins (PP10, PP11, PP12) was investigated in ethanol/acetic acid-fixed paraffin-embedded human term placentae. PP8 was found mainly in both the cytoplasm and the nucleus of trophoblast cells (chorion) and syncytiotrophoblast (villi). PP9 was found in the cytoplasm of trophoblast cells (chorion), the fibrous part of interstitial connective tissues (villi), and the cytoplasm of histiocytes (villi, amnion, and decidua). PP10 was found in the cytoplasm of epithelium (amnion) and in both the cytoplasm and the nucleus of syncytiotrophoblast (villi). PP12 was found in the cytoplasm of histiocytes in decidua, amnion, and chorion and the cytoplasm of syncytiotrophoblast (villi). In addition, stains for PP8, PP10, and PP12 were taken up by the cytoplasm of histiocytes found in amnion, villi, the intervillous space, and decidua, in contrast to PP11, which was found to be specific to the cytoplasm of trophoblast cells (chorion and villi). Possible clinical applications of these findings are discussed.

Cell Nucleus↗
PubMed1979

Sexual transmission of hepatitis B surface antigen. Infection of husbands by HBsAg carrier-state wives.

The husbands of 68 hepatitis B surface antigen (HBsAg) carrier-state wives were tested for the presence of hepatitis B surface antibody (HBsAb) and antigen (HBsAg) to assess possible transmission of HBsAg. Eight (11.8%) of the 68 husbands gave negative results for HBsAg and 22 (32.4%) positive results for HBsAb. Furthermore, eight (26.7%) of 30 husbands with presumed HBsAg transmission from their wives developed acute viral hepatitis after marriage, and e antigen (eAg) was detected in the serum from all eight wives. Although HbsAg was not detected in specimens of sputum and cervical mucus of carrier-state women by reverse passive haemagglutination, it was detected in the vaginal discharge of women during days 1--6 of the menstrual cycle at a rate ranging from 20--60%. Thus, sexual transmission of HBsAg seems to occur, particularly if sexual contact takes place during or immediately after menstruation.

Carrier State↗
PubMedDate not supplied

Clinical study of recombinant hepatitis B vaccine.

The efficacy and safety of a recombinant yeast-derived hepatitis B vaccine were evaluated in 209 subjects after three administrations at 0, 4 and 20 weeks. Subjects were divided into four groups given 5 micrograms vaccine subcutaneously, 10 micrograms subcutaneously, 10 micrograms intramuscularly and 20 micrograms subcutaneously to define the effective dose and to compare the effect of administration. Seroconversion of the antibody to hepatitis B surface antigen after the third vaccination reached 96.6% in the group given 5 micrograms vaccine subcutaneously and 100% in the other groups. The final geometric mean antibody titres were 700 IU/l in subjects given 5 micrograms subcutaneously, 2004 IU/l in those given 10 micrograms subcutaneously, 4674 IU/l in those given 10 micrograms intramuscularly and 3342 IU/l in those given 20 micrograms subcutaneously. In the groups given 10 micrograms, the early seroconversion rate of the antibody to hepatitis B surface antigen and the geometric mean antibody titres after the third vaccination were significantly higher in subjects administered intramuscularly than subcutaneously (P less than 0.05). No major adverse effects were observed and minor reactions were the same as, or less than, those reported for the plasma-derived vaccine. Before and after administration, no significant fluctuation in the yeast antibody titre was observed. These results demonstrate the efficacy and safety of the yeast-derived vaccine, and show that 10 micrograms was the effective dose.

Antibody Formation↗